Generic Name and Formulations:
Clindamycin (as phosphate) 1%; foam; contains alcohol.
Indications for EVOCLIN:
Wash and dry skin. Apply once daily. Dispense an amount that will cover the affected area(s) into cap or other cool surface. Pick up a small amount of foam with fingertips and massage into affected area(s) until foam disappears.
History of regional enteritis, ulcerative or antibiotic-associated colitis (including pseudomembranous colitis).
Atopic patients. Discontinue if significant diarrhea, irritation, or dermatitis occurs. Avoid contact with eyes, mouth, lips, other mucous membranes or broken skin. Discontinue if no improvement after 6–8 weeks or if condition worsens. Product is flammable. Pregnancy (Cat.B). Nursing mothers: not recommended.
May potentiate neuromuscular blockers. Cross-resistance may occur with erythromycin. Prolonged and/or worsened severe colitis with antiperistaltic agents (eg, opiates, diphenoxylate with atropine).
Application site reactions (eg, burning, pruritus, dryness), headache, irritation, gram (–) folliculitis, abdominal pain, Gl disturbances; rare: diarrhea, pseudomembranous colitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma